# EDGAR Filing Document

**Accession Number:** 0001778016
**File Stem:** 0000950170-25-102964
**Filing Date:** 2025-8
**Character Count:** 9275
**Document Hash:** aa15ee4d928c99de15a08baa1bedd3ca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-102964.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0000950170-25-102964

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** I-Mab
- **CENTRAL INDEX KEY:** 0001778016
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91674
- **FILM NUMBER:** 251184696

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 400, 2440 RESEARCH BLVD
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** (301) 670 2800

**MAIL ADDRESS:**
- **STREET 1:** SUITE 400, 2440 RESEARCH BLVD
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Everest Medicines Ltd
- **CENTRAL INDEX KEY:** 0001783937
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** SUITE 6601-6606, PLAZA 66, TOWER 1
- **STREET 2:** 1266 WEST NANJING ROAD
- **CITY:** SHANGHAI
- **PROVINCE COUNTRY:** F4
- **BUSINESS PHONE:** 862180125755

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** SUITE 6601-6606, PLAZA 66, TOWER 1
- **STREET 2:** 1266 WEST NANJING ROAD
- **CITY:** SHANGHAI
- **PROVINCE COUNTRY:** F4

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_a.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**I-MAB**

*(Name of Issuer)*

**Ordinary shares, par value US$0.0001 per share**

*(Title of Class of Securities)*

**44975P103**

*(CUSIP Number)*

**Yuan MA**<br>36 ROBINSON ROAD

#20-01 CITY HOUSE<br>Singapore U0 068877<br>86 21 8012 3250

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/05/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **44975P103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Everest Medicines Limited** | Name of reporting person<br>**Everest Medicines Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**42524716.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**42524716.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**42524716.00** | Aggregate amount beneficially owned by each reporting person<br>**42524716.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**16.1%** | Percent of class represented by amount in Row (11)<br>**16.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary shares, par value US$0.0001 per share

**(b) Name of Issuer:**
I-MAB

**(c) Address of Issuer's Principal Executive Offices:**
2440 Research Boulevard, Suite 400, Rockville, MD, 20850

**Item 4. Purpose of Transaction**

The information set forth in or incorporated by reference in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4.

The Reporting Person purchased the aforementioned securities for investment purposes with the aim of increasing the value of its investments and the Issuer. Subject to applicable legal requirements, the Reporting Person may purchase additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Person's ownership of the Issuer's securities, other opportunities available to the Reporting Person, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Person may dispose of all or a portion of their securities of the Issuer at any time. The Reporting Person reserves the right to increase or decrease its holdings on such terms and at such times as each may decide.

Except as set forth in this Item 4 and Item 6 below, the Reporting Person does not have a present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Securities Exchange Act of 1934 (the "Act"). However, the Reporting Person reserves the right to propose or participate in future transactions which may result in one or more of such actions, including but not limited to, an extraordinary corporate transaction, such as a merger, reorganization or liquidation, sale of a material amount of assets of the Issuer or its subsidiaries, or other transactions which might have the effect of causing the ordinary shares to become eligible for termination of registration under Section 12(g) of the Act. The Reporting Person also retains the right to change their investment intent at any time, to acquire additional ordinary shares or other securities of the Issuer from time to time, or to sell, distribute or otherwise dispose of all or part of the ordinary shares beneficially owned by it in any manner permitted by law (including pursuant to a sale or distribution plan adopted pursuant to Rule 10b5-1 under the Act). The Reporting Person may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Everest Medicines Limited holds 15,846,150 ADSs and 6,078,571 ordinary shares of I-MAB. The percentage of the class of securities identified putsuant to Item 1 beneficially owned by the Reporting Person is based on a total of 264,485,455 ordinary shares issued and outstanding immediately after the referenced underwritten offering, as described in the prospectus supplement dated August 1, 2025 filed by I-MAB with the SEC on August 4, 2025.

**(b)**
Everest Medicines Limited has sole voting and dispositive power over 15,846,150 ADSs and 6,078,571 ordinary shares.

**(c)**
Except as disclosed in this Schedule 13D, neither the Reporting Person nor, to the knowledge of the Reporting Person, any of the persons listed in Exhibit A hereto, has effected any transactions in the securities of the Issuer during the last 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in or incorporated by reference in Items 3, 4 and 5 of this Schedule 13D is incorporated by reference into this Item 6.

Except as described above or elsewhere in this Schedule 13D or incorporated by reference in this Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Everest Medicines Limited

**Signature:** /s/ Ian Ying WOO

**Name/Title:** Ian Ying WOO, CFO&President

**Date:** 08/05/2025